{"filing":{"accession_number":"0001193125-26-290485","cik":"0001612042","ticker":"ASND","company_name":"Ascendis Pharma A/S","form":"6-K","filing_date":"2026-06-30","report_date":null,"primary_document":"d93159d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1612042/000119312526290485/d93159d6k.htm"},"events":[{"id":15042,"run_id":13421,"accession_number":"0001193125-26-290485","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The 6-K discloses new radiographic data from Week 104 of the completed ApproaCH pivotal trial of TransCon CNP in children with achondroplasia, presented at an international conference. This represents a material clinical milestone—positive efficacy and safety data from a Phase 3 trial supporting a lead product candidate—but does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or restatement). The disclosure is clearly operational/strategic (clinical trial results) rather than financial, governance, or legal, making operational_other the most appropriate classification.","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-06-30","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":12662,"accession_number":"0001193125-26-290485","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The 6-K discloses new radiographic data from Week 104 of the completed ApproaCH pivotal trial of TransCon CNP in children with achondroplasia, presented at an international conference. This represents a material clinical milestone—positive efficacy and safety data from a Phase 3 trial supporting a lead product candidate—but does not fit the discrete event categories (not an earnings release, M\u0026A activity, executive change, or restatement). The disclosure is clearly operational/strategic (clinical trial results) rather than financial, governance, or legal, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-01T02:21:39.423955+00:00","company_name":"Ascendis Pharma A/S","ticker":"ASND","filing_date":"2026-06-30"}]}